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Else Dapat1,2,4*, Sonia Jacinto2† and Thomas Efferth3,4†Abstract
Background: Bioactivity-guided fractionation of extracts of Aglaia loheri Blanco (Meliaceae) yielded a cytotoxic
isolate, termed Maldi 531.2[M + H]+. This phenolic ester was further investigated for its in vitro cytotoxicity toward
human CCRF-CEM leukemia cells and their multi-drug resistant (MDR) subline, CEM/ADR5000. The intrinsic
mitochondrial membrane potential (ΔΨm) and induction of apoptosis by this isolate were evaluated.
Methods: Chromatography techniques, mass spectrometry and proton NMR were employed to isolate Maldi
531.2[M + H]+. XTT cell proliferation and viability assay was used for cytotoxic test, and JC-1[5’,5’,6,6’,-tetrachloro-
1,1’,3,3’-tetraethylbenzimidazoyl carbocyanine iodide was used to assess ΔΨm and initiation of apoptosis; Annexin
V/FITC-PI staining was employed to analyse apoptosis.
Results: Maldi 531.2[M + H]+ was cytotoxic towards both CCRF-CEM and CEM/ADR5000 cells with IC50 values
of 0.02 and 0.03 μM, respectively. The mitochondrial membrane potential (ΔΨm) of MDR cells was significantly
reduced in a dose-dependent manner leading to apoptosis as detected by flow cytometric Annexin
V-FITC/ PI staining.
Conclusion: Maldi 531.2[M + H]+ may be a potential anti-cancer drug candidate whose mode of action include
reduction of the mitochondrial membrane potential and induction of apoptosis.
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Annexin V-FITCBackground
Hematologic malignancies account for a considerable
percentage of cancers worldwide [1]. A common type of
this malignancy is acute lymphoblastic leukemia (ALL).
ALL involves rapid transformation of a single normal
progenitor cell [2] triggered by several factors associated
with exposure to radiation and chemicals. These factors
cause genetic damage, resulting in complete destruction
of cellular regulatory controls on proliferation, differenti-
ation and apoptosis [3-6]. Since leukemia is a systemic
disease, its cure depends on chemotherapy [7] rather
than surgery. A new approach to increasing effectiveness* Correspondence: elsegdapat40@gmail.com
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reproduction in any medium, provided the orto chemotherapy includes the use of various molecularly
targeted drugs derived from natural plant products [8].
The research on Aglaia loheri was part of a larger project
to explore the potential medicinal value of plants endemic
to the mountain area of Kanawan, Morong (Bataan,
Philippines) which is part of the ancestral domain of indi-
genous people called Aetas. From personal communica-
tions with the indigenous people, it was learned that some
of the plants were used by the Aetas for medicinal or
nutritional purposes. A. loheri is actually part of their diet.
However, due to accounts from published literature on
other Aglaia species, we hypothesized that A. loheri may
be cytotoxic towards cancer cells.
The genus Aglaia (family Meliaceae) is an important
source of unique bioactive natural products, which contain
a cyclopenta[b]tetrahydrobenzofuran skeleton and include
more than 50 naturally occurring derivatives collectivelytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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found to be effective against thymidine kinase-
deficient Herpes simplex virus type 1 (HSV-1) and
phosphonoacetate-resistant HSV-1 strains [9], includ-
ing human amoebiasis caused by Entamoeba histolytica
[10]. These compounds were shown to inhibit necrosis
factor (NF)-B induced gene activation in human T cells
[11], HIV-1 infection [12], and initiation and promotion of
chemically-induced cancer on mouse skin [13]. Amide
esters are structurally related to bisamides and flavaglines
from Aglaia sp. [14] and exhibited anti-fungal [15], insec-
ticidal [16], anti-tuberculosis and anti-viral activities [17].
Remarkably, this class of compounds also induces apop-
tosis in resistant human cancer cells [18-20]. For example,
silvestrol, a novel compound from Aglaia was active
against cancer cells in vitro and in vivo [20,21]. It induced
apoptosis in prostate carcinoma cells through the mito-
chondrial/apoptosome pathway without activation of
caspase-3 or −7 [19] and in human B-leukemia cells, by
reducing Mcl-1 expression due to inhibition of translation
with subsequent mitochondrial damage [21].
In the present study, crude extracts from leaves of A.
loheri Blanco were subjected to bioassay-guided isolation
by means of various chromatography techniques. The
resulting active principle was further analyzed and char-
acterized by mass spectroscopy and nuclear magnetic
resonance (NMR). The isolated active principle was
investigated for its cytotoxicity towards cancer cells. The
mitochondrial membrane potential (ΔΨm) was analyzed
as a key indicator of cell viability [22,23] and induction
of apoptosis as an important parameter of cell integrity.
Methods
Kits and reagents
Analytical grade ethyl acetate and hexane were used for
extraction. Analytical grade chloroform and methanol
were used for gravity column chromatography. Silica gel
60 G 0.063-0.200 mm (Merck; Germany) was used for
gravity column chromatography. Pre-coated gel 60 G F254
plates 0.25 mm thick (Merck, Darmstadt, Germany) were
used for thin layer chromatography (TLC). Iodine crystals
and UV were used to visualize separation monitored by
analytical TLC. Doxorubicin was purchased from Sigma
Chemical Company, USA. Dimethyl sulphoxide (DMSO)
(Sigma, St. Louis, MO, USA) was used to dissolve the test
samples. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) were purchased from Promega,
USA. XTT (2,3-bis- (2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide), XTT labelling reagent
(sodium 3’-[1-phenylaminocarbonyl)-3,4-tetrazolium]-bis
(4-methoxy-6-nitro) benzene sulfonic acid hydrate) and
electron-coupling reagent (N-methyl dibenzopyrazine
methyl sulphate [0.383 mg/mL (1.25 mM)] in sterile phos-
phate buffered saline (PBS) were purchased from Roche(Mannheim, Germany). JC-1 and annexin V-FITC de-
tection kit was obtained from eBioscience (Frankfurt,
Germany); propidium iodide and carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) from Sigma-Aldrich
(Taufkirchen, Germany).
Cell culture and supplements
Human colon cancer cell line (HCT116) was obtained from
American Type Culture Collection (ATCC, Manassas,
Virginia, USA). The cells were grown in McCoy’s 5a
modified medium (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10% inactivated fetal bovine serum (Invi-
trogen, USA) and 1% penicillin-streptomycin (100 U/mL)
(Invitrogen, USA). The cell line was maintained in a
humidified incubator containing 5% CO2 at 37°C.
Human leukemic cells, CCRF-CEM and their multi-
drug-resistant subline, CEM/ADR5000 [24], were obtained
from Dr. Axel Sauerbrey (Department of Pediatrics,
University of Jena, Germany). The cells were maintained
in a humidified environment at 37°C and 5% CO2. The
cells were grown in RPMI 1640 [−] L-glutamine containing
1% penicillin (10 U/mL), streptomycin 10 μg/mL, and 10%
heat-inactivated fetal bovine serum (FBS) (all obtained
from Gibco Invitrogen, Germany). Drug resistance of of
CEM/ADR5000 cells was maintained by weekly treatment
with 5000 ng/mL. P-glycoprotein expression without over-
expression of other ATP-binding cassette transporters in
CEM/ADR5000 cells has been reported [25,26].
Peripheral blood mononuclear cells (PBMC) were
isolated from freshly collected whole blood sample using
Ficoll-paque solution (Histopaque-1077) (Sigma) by cen-
trifugation [27]. The cells were washed twice with RPMI-
1640 and were re-suspended in same culture medium
(RPMI-1640). Cells (0.5 mL of cell suspension) were
seeded in a 24-well sterile plate at a density of 106/mL
prior to activation with 0.5 mL of 10 μg/mL of phytohem-
agglutinin (PHA). Addition of 0.5 mL of PHA into each
well (0.5 mL RPMI-1640 to one control group) adjusted
the number of cells to a final density of 5 × 105/mL per
well. The cells were incubated at 37°C and 5% CO2 for
3 days prior to XTT assay.
Collection of plant material
Fresh and mature leaves of A. loheri Blanco were col-
lected in the morning from its natural habitat in Morong
(Bataan, Philippines). Voucher specimen of the plant
under Accession No. 14612 was deposited and authen-
ticated by the Jose Vera Santos Herbarium of the Insti-
tute of Biology, University of the Philippines (Diliman,
Quezon City, Philippines). The leaf specimens were
washed and air-dried in a well-ventilated room at Pavilion
IV, Institute of Biology, University of the Philippines
(Diliman, Quezon City, Philippines). After drying, the leaf
samples were homogenized using a blender.
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Homogenized leaf samples were soaked in ethanol for
48 h. The soluble ethanolic extract was filtered and the
filtrate was concentrated in vacuo at 40°C using a rotary
evaporator (Heidolph, Schwabach, Germany) yielding a
concentrated ethanolic crude extract (ECE). ECE was
assayed for cytotoxicity by using MTT assay [28] against
HCT116 cells. The concentrated ECE was diluted in
approximately 200 mL ethanol and was partitioned
exhaustively with hexane and ethyl acetate successively.
Both hexane soluble extract and ethyl acetate soluble
extract were concentrated in vacuo at 40°C separately
which yielded concentrated hexane extract (HE) and
concentrated ethyl acetate extract (EAE). Finally, the two
concentrated crude fractions were tested for their cyto-
toxicity by the MTT assay.
Determination of band profiles by thin layer
chromatography (TLC)
A small amount of the EAE was spotted 5 cm above the
bottom edge of the 5 × 7.5 cm TLC plate using a very
thin glass tube. The extract was air-dried on the TLC
plate which was then placed in eluent in the developing
chamber so the bottom of the plate is in the liquid.
Several eluents with increasing/decreasing concentration
ratio (ranging from 1:9 to 9:1) of chloroform to metha-
nol were prepared to determine the best solvent system
that separates components of the mixture in the extract;
the 9:1 chloroform-methanol was used as solvent system
in column chromatography.
Gravity column chromatography
EAE was fractionated using gravity column chroma-
tography. The glass column was packed with Silica gel
Merck® grade 9385, pore size 60 Å, 230–400 mesh. A 9:1
chloroform-methanol was used as an eluting solvent in
the first batch of fractionation to produce column frac-
tions (CF). Increasing gradient concentrations of hexane
and ethyl acetate were used in the next batch to produce
sub-fractions (SF). An appropriate amount of extract
was applied to the top of the column to prevent over-
loading: 1.0 g of extract to 1 kg of silica gel was packed
in the glass column. The eluates (20 mL) were collected
in test tubes and separation was monitored by TLC.
Those eluates with same TLC profiles were pooled
together, concentrated in a rotary evaporator and labeled
as chromatographic fractions (CF). TLC profiles of the
eluates were visualized by using UV light (100 nm –
315 nm) to detect the presence of aromatic compounds
and 10% vanillin-sulfuric acid as spray reagent to detect
groups of unsaturated compounds on the TLC plate.
Pooled fractions were then subjected to MTT assay.
Fractions that showed the highest cytotoxic activity were
further fractionated in gravity column chromatography(2 cm in diameter and 37 cm long) through gradient
elution. An active isolate was finally purified by high
performance liquid chromatography (HPLC) using Silica–
C18 as packing material and methanol–water as the
mobile phase and was submitted for mass spectrometry to
determine the molecular weight and nuclear magnetic
resonance (NMR) analysis to determine the possible struc-
ture of the compound.
Cell viability assays
To determine the cytotoxic effects of the crude extract
and isolated compound, cellular growth of both untrea-
ted and treated cells was monitored using the MTT
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay [28]. A master dilution plate (MDP) was
prepared before subjecting the cells to MTT assay. Each
MDP contained A. loheri extracts/isolate in varying con-
centrations ranging from 125–1000 μg ×mL-1 for crude
extracts and 7.8-62.5 μg ×mL-1 for pure isolates. Cells
were harvested and seeded in a sterile, flat-bottom 96-
well microtiter plates at a density of 3.5 × 105 mL-1, then
were incubated for 24 h at 37°C in a humidified incubator
with 5% CO2. After 24 h incubation, 10 μL from MDP
preparation were added to the cells in each well to make
final concentrations of 50, 25, 12.5 and 6.25 μg ×mL-1 for
crude extracts and 7.8, 15.6, 31.25, 62.5 μg ×mL-1 for the
pure isolate. The cells were then incubated for 72 h. After
incubation, the media was discarded, and 20 mL of MTT
were added to each well. The MTT solution was made by
dissolving 5 mg MTT (Sigma-Aldrich) per mL phosphate
buffer solution. The cells were again incubated for 4 h
before adding 150 mL of DMSO (Sigma, USA) to dissolve
the formazan crystals. At least two independent tests with
three replicates each were performed in this experiment.
The absorbance of the formazan crystals was then taken
with dual wave-measurement at 570 nm and 620 nm
using a Bio-Rad microplate reader (Munich, Germany).
Furthermore, a colorimetric XTT-based assay was
applied according to the manufacturer’s protocol. Two
independent tests were conducted. Cells grown in cell
culture flasks were harvested. A 100 μL aliquot of 2.0 ×
105cells/mL were seeded into each well of a 96-well mi-
crotiter cell culture plate, and were immediately treated
with various concentrations (0.001 to 30 μM) of Maldi
531.2[M +H]+, the isolate, with six replicates per dose
level. Two sets of control groups were employed: one
control group was suspended only in nutrient media
while another was suspended in nutrient media containing
0.02% dimethyl sulfoxide (DMSO), the solvent to dissolve
Maldi 531.2[M +H]+. After incubating for 72 h at 37°C
and 5% CO2, 50 μL of a mixture of XTT labeling re-
agent and electron-coupling reagent in sterile phos-
phate buffered saline (PBS) were added and incubated
at 37°C for 4 h. The absorbance of the water-soluble
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using a Tecan microplate reader (Sunrise-Basic Tecan,
Crailsheim, Germany) and is directly proportional to the
number of living cells in the culture. The viability of the
treated cells was compared to the viability of the DMSO-
treated cells. Percent growth inhibition (I%) was calculated
using the formula: I% = 100 [1-(At /Ac) where At is the
absorbance of the Maldi 531.2[M +H]+ -treated cells and
Ac is the absorbance of the DMSO-treated cells. The IC50
concentration was estimated by logarithmic regression [29]
where IC50 is the inhibitory concentration of Maldi 531.2
[M+H]+ required to inhibit growth of 50% of the incu-
bated cell population.
Mitochondrial membrane potential (ΔΨm) analysis
JC-1 is a membrane permeable dye that selectively accu-
mulates in the mitochondria, where it reversibly changes
color as membrane potential (ΔΨm) increases over
values of about 80–100 mV. JC-1 is widely used for
quantifying mitochondrial membrane potential by meas-
uring the fluorescence intensities and is therefore an in-
dicator of initiation of cell apoptosis [30]. To assess the
effect of Maldi 531.2[M +H]+ on ΔΨm, 106 cells were
incubated for 24 and 48 h (37°C, 5% CO2) with three
doses (0.05, 0.5 and 1.0 μM). Two aliquots of cells were
treated with the control drugs: 10 μg/mL doxorubicin
and 0.05 μM CCCP (Sigma-Aldrich) and incubated at
37°C and 5% CO2. An incubation time of 10 min was
sufficient, because of the rapid stimulation of membrane
polarization by CCCP. An incubation of more than
10 min with CCCP greatly reduces the fluorescence in-
tensity in the FL2 channel (564–606 nm) converting a
red fluorescence signal to a green signal. Afterwards, the
cells were stained with JC-1 for 30 min at 37°C and 5%
CO2. The membrane sensitive JC-1 dye was prepared ac-
cording to the manufacturer’s recommended concentra-
tion of 2.5 μg/million cells/mL from a stock solution of
1 mg/mL prior to use (eBioscience, Germany). The dye
was pre-warmed in a 37°C water bath prior to addition
to treated and untreated cells. Stained cells were then
analyzed by flow cytometry (FACS®Calibur (Becton
Dickinson) and CellQuest Pro (Becton Dickinson) ana-
lysis software according to the settings suggested in the
protocol (AccuriCytometers, St. Ives Cambs, UK).
Annexin V/FITC binding assay
Annexin V/FITC staining was performed to evaluate
apoptosis induced by Maldi 531.2[M +H]+. Annexins
are calcium-dependent, phospholipid-binding proteins
that specifically bind to phosphatidylserine (PS) in the
plasma membrane [31]. Under normal physiological
conditions, PS is predominantly located in the cytosolic
layer of the plasma membrane. Upon initiation of apop-
tosis, PS is translocated from the cytosolic layer of theplasma membrane to the extracellular layer for recogni-
tion and uptake by phagocytes, where it can be detected
by fluorescently-labeled Annexin V (eBioScience). Cells
were exposed to the active isolate (0.05, 0.5, 1.0 μM) and
incubated for 24 h at 37°C and 5% CO2. For positive
controls, cells were treated with 10 μg/mL doxorubicin
(Sigma-Aldrich) and 10 μM camptothecin separately and
were also incubated for 24 h at 37°C and 5% CO2. The
annexin-V assay was performed according to the proto-
col provided in the annexin V-FITC detection kit
(eBioScience). Briefly, 5.0 × 105 treated cells were re-
suspended in 50 μL of 1× annexin-staining buffer con-
taining 10 mM HEPES, 140 mM NaCl, and 2.5 mM
CaCl2 (pH 7.4) and incubated in the dark with 2.5 μL of
annexin V conjugate for 15 min at 25°C. After incuba-
tion, the final volume of each sample was adjusted to
500 μL followed by the addition of 1.25 μL of 1 mg ×mL-1
propidium iodide (PI). Apoptotic cells were analyzed using
a FACS®Calibur (Becton Dickinson, Heidelberg, Germany)
and CellQuest Pro (Becton Dickinson) analysis soft-
ware. Excitation and emission settings were 488 nm,
515–545 nm (FL1 channel) for annexin V-FITC and
564–606 nm (FL2 channel) for PI.
Statistical analysis
Data were expressed as mean ± SEM of two independent
tests. JC-1 and annexin V-FITC fluorescence intensity
data were subjected to one-way analysis of variance
followed by Tukey’s multiple comparison test. A prob-
ability of less than or equal to 0.05 was considered statis-
tically significant to reject the null hypothesis.
Results
Bioactivity-guided isolation of an active fraction from
A. loheri
Approximately 15.23 g (1.96%) of ethyl acetate crude ex-
tract were obtained from 777 g of dried ground leaf
samples of A. loheri after solvent partitioning. Cytotox-
icity of the extracts was tested towards HCT116 by the
MTT assay. The ethyl acetate fraction was cytotoxic
exhibiting an IC50 concentration of 5.47 μg/mL. Ethyl
acetate extract was subjected to gravity column chroma-
tography utilizing silica gel-60 as stationary phase
packed in 3.5 cm diameter, 37 cm long glass column,
and 9:1 chloroform-methanol as mobile phase. This
chromatographic separation yielded 10 column fractions,
where CF1 revealed the highest cytotoxicity (IC50 of
3.82 ± 0.02 μg/mL). For comparison, doxorubicin was
used as control drug and revealed an IC50 of 3.74 ± 0.14
(Table 1). Further gradient fractionation of CF1 yielded
11 sub-fractions (SF) whose IC50 values are shown in
Table 2. SF9 was the most cytotoxic one. Therefore, this
fraction was subjected to HPLC to further purify the ac-
tive compound. Four distinct peaks were generated. The
Table 1 IC50 values of gravity column chromatographic
fractions of Aglaia loheri extracts run in silica gel-60 and
9:1 chloroform: methanol tested for toxicity against HCT
116
Column fraction (CF) IC50 (μg/mL)
1 3.82 ± 0.02
2 3.84 ± 0.07
3 3.88 ± 0.10
4 3.86 ± 0.12
5 3.98 ± 0.08
6 3.84 ± 0.09
7 5.07 ± 0.16
8 26.60 ± 2.60
9 13.50 ± 0.54
10 NLI
Doxorubicin 3.74 ± 0.14
NLI: No Logarithmic Interpolation indicating absence of toxicity.
Bold Texts: Most cytotoxic fraction of Aglaia loheri extracts.
Table 3 IC50 values of eluates collected from individual
HPLC peaks
Peaks Amount collected (mg) IC50 (μg/mL)
1 0.2 5.25 ± 0.54
2 0.3 21.35 ± 0.67
3 2.0 4.52 ± 0.71
4 0.4 5.57 ± 0.36
Doxorubicin 4.10 ± 0.28
Bold Texts: Most cytotoxic HPLC fraction from SF9 (Table 2).
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while peak 4 was greenish in color. Cell viability test
results after cytotoxicity assay are shown in Table 3.
Chemical characterization of the bioactive A. loheri fraction
Bioactivity-guided fractionation of a crude extract of A.
loheri leaves led to the isolation of a bioactive component
(peak 3), an amorphous white powder of approximately
2.0 mg (total yield = 1.3%) which exhibited a molecular
ion peak at m/z 531.2[M +H]+ (Figure 1), which was
termed Maldi 531.2[M +H]+.Table 2 Gravity column chromatographic sub-fractions
(SF) of A. loheri CF1 run in silica gel-60 and various
gradients of increasing amount of ethyl acetate
Gradient






2 83:17 42.06 ± 0.67
3 81:19 35.17 ± 4.63
4 78:22 31.61 ± 6.52




9 59:41 3.96 ± 0.07
10 55:45 4.98 ± 0.50
11 50:50 11.92 ± 1.29
Doxorubicin 4.31 ± 0.06
NLI: No Logarithmic Interpolation indicating absence of toxicity.
Bold Texts: Most cytotoxic sub-fraction of CF1 (Table 1).The chemical shift values and their assignment to
Maldi 531.2[M +H]+ was based on its 1H NMR
spectrum (Table 4). The 1H NMR spectrum indicated
that Maldi 531.2[M +H]+ contains aromatic rings (δ 6.7-
7.9 ppm), a phenolic group (δ 4.54 ppm), methoxy
groups (δ 3.61-3.66 ppm), and several aliphatic chain
structures (δ 1.87-3.61 ppm). As can be deduced from
the one-dimensional NMR analysis, the probable
structure of Maldi 531.2[M +H]+ may be an aromatic
(phenolic) ester.
Cytotoxicity of Maldi 531.2[M + H]+ towards sensitive and
multidrug-resistant tumor cells
Figure 2 shows the effects of Maldi 531.2[M +H]+ on
the viability of CCRF-CEM cells and their multidrug-
resistant sub-line, CEM/ADR5000. The active principle
reduced mean cell viability of the two human leukemic
cell types in a dose-dependent manner. A significant
decrease in cell viability was observed at 0.03 μM and
this further decreased with increasing concentration.
Few cells survived at a dose range of 0.3 to 30 μM. The
IC50 of Maldi 531.2[M +H]
+ on CCRF-CEM cells was
0.02 μM and on CEM/ADR5000 cells 0.03 μM, indica-
ting that CEM/ADR5000 cells were only 1.5-fold cross-
resistant to Maldi 531.2[M +H]+. For comparison,
CEM/ADR5000 cells were more than 1000-fold resistant
towards doxorubicin compared to parental CCRF-CEMFigure 1 MALDI MS spectrum of an isolate from Aglaia loheri.
[M + H]+ = molecular ion peak, m/z 531.2; * denotes background
peaks from MALDI matrix.
Table 4 1H NMR spectral data of Maldi 531.2[M + H]+
PPM Multiplicity J coupling TYPE
1.87 m NHCO phenyl
2.70 s -OCO-alkyl or phenyl
3.19 m N-propyl CH2OH
3.42 m Methyl CH3OH
3.61 m CH2-OH
3.62 s - -OCH3
3.66 s - -OCH3
3.72 m - -OCO-CH3
3.82 d 6.72 -OCO- phenyl or methyl
3.97 dd 7.92; 6.24 Isopropyl CH-OH
4.23 d 14.22 -OCO-phenyl or n-propyl
4.58 bs - Phenolic –OH?
5.49 -OCO-phenyl
6.17 d 1.92 Aromatic H
6.28 d 1.80 Aromatic H
6.61 dd 8.24; 3.00 Aromatic H
6.89 d 6.90 Aromatic H
6.99 m Aromatic H
7.03 m Aromatic H
7.11 dd 8.94; 3.00 Aromatic H
7.90 s - Aromatic H
s: singlet; bs: broad singlet; d: doublet; dd: doublet of doublet; m: multiplet.
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HCT 116 cells yielding a mean IC50 of 3.9 μg/mL (data
not shown). However, an MDR suspension cell line and
its corresponding sensitive line, were used for the later
experiment due to the ease of maintaining and handling
suspension cell line over that of adherent cell line which
need constant trypsinization. Although it is importantFigure 2 The effect of Maldi 531.2[M + H]+ on CCRF-CEM and
CEM/ADR5000 cells determined by XTT assay after incubating
the cells with the isolate for 72 hr. in a humidified
environment. Values are means ± SEM of six replicates each of two
independent experiments.that the cytotoxic agent be determined to be specific
only to cancer cells, it is an established fact that many of
the presently used cancer chemotherapeutic agents are
not specific against tumor/ malignant cells only. They
also affect fast dividing normal cells such as those in the
blood, in the digestive tract and other organs leading to
a number of side effects like vomiting, hair loss, and the
like. Hence, a number of studies that seek to mitigate
these effects on normal cells such as on drug delivery
specifically targeting cancer cells are being actively ex-
plored. We also suggest this as an offshoot of this study
as part of the recommendation or future directions or
follow up studies.
In connection with this, a cell viability test was per-
formed separately using PHA-activated peripheral blood
mononuclear cells (PBMC). After exposing the cells with
various concentrations of Maldi 531.2[M +H]+, it was
found to be cytotoxic (IC50: 50.86 μM) as seen in Figure 3.
However, despite its cytotoxic effects on PBMC, the level
of toxicity is much less than its effects toward CCRF-CEM
and ADR5000/CEM cells.
Quantitation of intrinsic mitochondrial membrane potential
by flow cytometry
Figure 4 shows the mitochondrial membrane potential of
CEM/ADR5000 cells treated for 24 and 48 h with various
doses of Maldi 531.2[M +H]+. A significant ΔΨm re-
duction was observed in cells treated with the active
principle in a dose-dependent manner 24 h after treat-
ment compared with untreated cells. A further significant
reduction of ΔΨm with Maldi 531.2[M +H]+-treated cells
was observed after 48 h. However, reduction in Maldi
531.2[M +H]+-treated cells was not significantly different
from the positive controls doxorubicin and CCCP after
24 h, but significantly decreased in those cells treated with
0.5 and 1.0 μM Maldi 531.2[M +H]+ including those of
doxorubicin-treated cells after incubation for 48 h.Figure 3 Growth inhibition of Maldi 531.2[M + H]+ toward
peripheral blood mononuclear cells (PBMC) activated with
10 μg/mL PHA. Viability of PBMC was determined by XTT assay
after incubating the cells with the isolate for 72 hr. in a humidified
environment (37°C and 5% CO2). Values are means ± SEM of six
replicates each of two independent experiments.
Figure 4 Determination of mitochondrial membrane potential
(ΔΨm) in multidrug-resistant CEM/ADR5000 cells after 24 and
48 h exposure to Maldi 531.2[M + H]+. Data are means ± SEM of
the three replicates of two independent experiments; P < 0.05.
Untreated cells served as negative control and 10 μg/mL
doxorubicin (doxo) and 0.05 μM carbonyl cyanide 3-chlorophenyl
hydrazone (CCCP)-treated cells as positive controls. Significant
differences between are indicated by letters. After 24 hr treatment,
mitochondrial membrane potential (ΔΨm) of untreated cells (UT-S),
indicated by subset “a” is significantly different from the CCCP and
Maldi 531.2[M + H] + treated cells as indicated by subset “b”. Values
for CCCP and Maldi 531.2[M + H] + treated cells don’t show
significant differences from each other as belong to the same subset
“b”. Mitochondrial membrane potential (ΔΨm) of untreated cells
(UT-S), indicated by subset “x” is significantly different from the CCCP
and Maldi 531.2[M + H] + treated cells as indicated by subset “y”
and “z” for 48 hrs. Values of same subset at non-significant from
each other.
Figure 5 Measurement of apoptosis induction by Maldi
531.2[M + H]+in CEM/ADR5000 determined by incubation with
annexin V. Data are means ± SEM of three replicates of two
independent experiments with reference to their controls: Untreated
cells served as negative control; 10 μM camptothecin (CAMPT) and
10 μg/mL doxorubicin (doxo) - treated cells as positive control.
Significant differences in apoptotic activity between treatments are
indicated by various groups of subsets: Early - “abc”; late apoptosis -
“mno” and dead cells – “xy”. Cells treated with 0.05 μM Maldi 531.2
[M + H]+ did not show significant apoptotic activity compared to
negative control cells in all stages but significantly different from
cells treated with the positive controls and those cells treated with
0.5 and 1.0 μM Maldi 531.2[M + H]+ (P < 0.05). However, early
apoptosis in cells treated with 0.05 μM Maldi 531.2[M + H] + is not
significantly different from early apoptosis in cells treated with
1.0 μM but significantly different from 0.5 μM Maldi 531.2[M + H] +
treated cells. Bars of same subsets are not significantly different
from each other.
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Apoptosis was induced by Maldi 531.2[M +H]+ in a
dose-dependent manner (Figure 5). Compared with
untreated cells, early apoptosis did not significantly
differ in all treatments, but significantly increased in late
apoptosis in a dose-dependent manner. Compared with
camptothecin and doxorubicin-treated cells Maldi 531.2
[M +H]+ reduced the occurrence of early apoptotic, but
not late apoptotic and dead cells over time.
Discussion
Plant extracts usually contain many secondary meta-
bolites with varying bioactivities [33]. In the present
investigation, we report the isolation of a cytotoxic com-
ponent of A. loheri, termed Maldi 531.2[M +H]+. The
cytotoxic properties of genus Aglaia was previously rec-
ognized by several groups [34]. Therefore, chemical
studies of the constituents of Aglaia focused primarily
on its toxic components resulting in the structure eluci-
dation of numerous phytochemical compounds [34]. To
date, Aglaia still represents a promising and rich source
for novel compounds. The isolation and purification of
Maldi 531.2[M +H]+ from A. loheri proved to be difficult,
because the isolated active component, was only present
in very low amounts. Despite this limitation, we were able
to investigate the bioactivity of Maldi 531.2[M +H]+towards cancer cells. Based on mass spectrometry ana-
lyses, this compound does not reveal any similarity with
other compounds isolated from other Aglaia species
[19,20]. As shown in Tables 5 and 6, the molecular ion
peaks of other Aglaia compounds are distinct from that of
our A. loheri isolate with m/z 531.2[M +H]+, indicating
that this represents a still unknown compound at least for
the genus Aglaia.
The isolate could possibly be related to bisamides and
flavaglines isolated by Kim et al. [19] and Salim et al.
[20] based on their cytotoxic and anticancer activities.
Cytotoxic activities were also observed in other isolated
compounds from A. tenuicaulis and A. forbesii such as
amide esters [14,17], which also demonstrated bioactivity,
e.g. anti-inflammatory and antimicrobial [35], antiviral
[17], and anticancer activities [36].
Phenolic esters inhibit carcinogenesis and reduce pro-
gression of cancer. Understanding the molecular basis of
their anticancer properties based on structure and activity
is important for the rational design of novel chemothe-
rapeutic agent [37]. Maldi 531.2[M +H]+ is a phenolic de-
rivative. Structure, lipophilicity and antioxidant properties
of the compounds are major factors affecting the cytotox-
icity of the compound due to the presence of a number of
hydroxyl (−OH) ring components and by the length of the
alkyl esters within the structure [37]. Lipophilicity goes
Table 5 List of unknown compounds previously isolated
from Aglaia edulis tested and found active against





Assigned name of the
compound
1 ^ ^ Aglaroxin A
2 584.1875* C31H31NO9Na* Aglaroxin A 1-O-Acetate
3 614.1999 C32H33NO10Na 3’-methoxyaglaroxin
A-1-O-Acetate
4 693.2421 C37H38N2O10Na 19,20-dehydroedulisone
A
5 * * Edulirin A
6 ** ** Edulirin A-10-O-Acetate
7 665.2469 C36H38H2O9Na 9,20-dehydroedulirin A
8 667.2608 C36H40N2O9Na Isoedulirin A
9 *** *** Isoedulirin B
10 316.1225 C17H20N2O2S Aglamide A
11 335.1079 C17H20N2O3SNa Aglamide B
12 323.1732 C18H24N2O2Na Aglamide C
13 254.1151 C14H17NO2Na Aglamide D
^ - known compound; * - similar to compound 2; ** - almost identical to
compound 5; *** - similar to compound 8.
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esters in the molecule, the greater its anticancer effect
[37]. For example, propyl esters are more effective against
tumor cells than methyl esters. In addition, –OH groups
are responsible for the antioxidant property in phenolic
compounds and their methylation diminishes their cyto-
toxicity [38]. However, lipophilicity and antitumor activity
were difficult to correlate, because other structural charac-
teristics may also account for the cytotoxicity of Maldi
531.2[M +H]+. This includes the position of the phenolic
substituents such as aromatic rings, carbons, carboxyl
group (C =O), and the alkyl chains.
Apoptosis is a fundamental, energy-dependent bio-
logical mechanism [31,39], which can be triggered by aTable 6 List of compounds previously isolated from
Aglaia foveolata tested and found active against cancer
(Salim et al., 2007) [20]
Compound
number
m/z Elemental formula Assigned name of the
compound
1 ^ ^ Silvestrol
2 675.2682* C38H40N2O8Na* ^^
3 * * ^^
4 * * ^^
5 673.2528 C38H38N2O8Na ^^
6 661.2529 C37H38N2O8Na ^^
7 ^ ^ Pyramidatine (bisamide)
8 559.3606 C13H52O7Na ^^
^ - known compound; ^^ - no assigned compound name; * - similar compounds.diverse array of stimuli, including phytochemicals
[40,41]. The reduction of ΔΨm by Maldi 531.2[M +H]+
in the present study strongly indicates initiation of
apoptotic events and inhibition of cell proliferation by
dissipation of the mitochondrial membrane potential.
Mitochondria are dynamic organelles, as they constantly
produce ATP [42]. A decrease of the mitochondrial
membrane potential results in loss of mitochondrial
function as it is an important component of the electro-
chemical gradient that is generated across the inner
mitochondrial membrane during electron transport and
oxidative phosphorylation [43]. Thus, ΔΨm is used as an
indicator of cell integrity [23], which is critical for
normal function of mammalian cells, maintaining the
function of mitochondrial proteins in the production
of ATP and reactive oxygen species (ROS). Alterations
of the mitochondrial membrane potential are indicative of
changes in mitochondrial metabolic activity (Acton 2004)
leading to cell cycle arrest and apoptosis [44].
Two biochemical assays were used to establish apop-
tosis: annexin V and JC-1 mitochondrial membrane
potential assay. The results of these two assays are suffi-
cient to establish the occurrence of apoptosis. JC-1 assay
evaluates extent of apoptosis through an end point
which is the loss of the mitochondrial membrane poten-
tial reflected by the entry and aggregation of the dye
inside the mitochondrial matrix. This event presupposes
that cytochrome C has been released, an event asso-
ciated with the loss of the mitochondrial membrane
potential. These two events however may not always go
together since it has been shown that loss of mitochon-
drial membrane potential is not necessarily required for
cytochrome c release [45].
In the case of the cytotoxicity effect of Maldi 531.2
[M + H] + as shown in cell viability tests and annexin
V-FITC binding assay, the difference in IC50 values
with XTT at 0.02-0.03 uM and the non-significant differ-
ence of cytotoxic effect at 0.05 uM with annexin V FITC
binding assay for apoptosis, relative to untreated cells, is
the time of observation. The cytotoxicity assay required
3 days (72 hours) of incubation with varied concentrations
of the drug/ natural product to determine the growth
inhibitory concentration which is the IC50 where 50% of
the population of cells have died already at a range of
concentration of 0.02 uM-0.03 uM for CCRF-CEM and
CEM/ADR5000 respectively. In the case of apoptosis,
observation time was only 24 hours after treatment pur-
posely to check only the ability of Maldi 531.2[M +H]+ to
“initiate” apoptosis. The optimum number of hours for
Maldi 531.2[M +H] +must not exceed 24 hours. If cells
were incubated longer than 24 hours with Maldi
531.2[M + H]+, i.e. after 32 or 48 hours, all cells were
dead which may significantly affect flow cytometric read-
ing for apoptosis. Annexin V-FITC binding assay was used
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cells with high affinity. Annexin V binding assay detects
apoptotic cells significantly even earlier than detections
based on alteration in gross DNA structures [31].
Although huge efforts have been undertaken to identify
P-glycoprotein inhibitors to overcome multidrug resistance
[46,47], clinical trials failed as yet [47,48]. Another concept
is to use non-cross-resistant cytotoxic compounds to kill
multidrug-resistant tumors. Remarkably, CEM/ADR5000
cells did not reveal considerable cross-resistance to Maldi
531.2[M+H]+ (1.5-fold), although CEM/ADR5000 cells
were highly resistant to anthracyclines, Vinca alkaloids,
taxanes and other established drugs as previously reported
[32]. This is a remarkable result, since it implies that Maldi
531.2[M+H]+ might be suitable to kill refractory tumors,
which are resistant to standard chemotherapy.
Conclusion
In conclusion, Maldi 531.2[M +H]+ showed considerable
activity against sensitive and multidrug-resistant tumor
cells by dissipation of the mitochondrial membrane
potential and induction of apoptosis. A. loheri and Maldi
531.2[M +H]+ may be promising for further drug devel-
opment. Further studies are required to unravel the full
potential of Maldi 531.2[M +H]+ as novel drug candi-
date for cancer therapy.
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